MLQ.ai | Stocks

T2 Biosystems (TTOO) News

Price: $1.82
Market Cap: $31.81M
Avg Volume: 174.70K

Country: US
Industry: Medical - Diagnostics & Research
Sector: Healthcare

Beta: 0.31
52W Range: $1.78-33.2
Website: T2 Biosystems

Related Tools

🗞️ Stock News Assistant

Get concise summaries, analyze trends, and ask questions about stock-related news.

Use Tool

✍️ AI Journalist

Input a topic and GPT will search the web, find relevants articles, and write an article based on the research.

Use Tool

T2 Biosystems Achieves Successful Defense of Patent for Direct-From-Whole Blood Pathogen Detection Method in the European Union

LEXINGTON, Mass., Sept. 20, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has successfully defended against an opposition filed against a key patent for its direct-from-whole blood detection method in the European Union.

globenewswire.com

T2 Biosystems to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

LEXINGTON, Mass., Aug. 27, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans to participate in the upcoming H.C. Wainwright 26th Annual Global Investment Conference.

globenewswire.com

T2 Biosystems to Attend Upcoming Investor Conferences

LEXINGTON, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans to participate in two upcoming investor conferences in August 2024:

globenewswire.com

T2 Biosystems, Inc. (TTOO) Q2 2024 Earnings Call Transcript

T2 Biosystems, Inc. (NASDAQ:TTOO ) Q2 2024 Earnings Conference Call July 29, 2024 4:30 PM ET Company Participants Trip Taylor - Investor Relations John Sperzel - Chairman & Chief Executive Officer John Sprague - Chief Financial Officer Conference Call Participants Kyle Mikson - Canaccord Operator Greetings, and welcome to T2 Biosystems, Inc. Second Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.

seekingalpha.com

T2 Biosystems Announces Commercial Expansion Through Malaysia and Indonesia Distributor

LEXINGTON, Mass., July 29, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistant genes, today announced the execution of a territory exclusive distribution agreement in Malaysia and Indonesia. Under the terms of the agreement, T2 Biosystems will sell the T2Dx® Instrument, the T2Bacteria® Panel, the T2Candida® Panel, and the T2Resistance® Panel through the newly appointed distributor.

globenewswire.com

T2 Biosystems to Report Second Quarter 2024 Financial Results and Business Updates on July 29, 2024

LEXINGTON, Mass., July 22, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report financial results for the second quarter 2024 and business updates after market close on Monday, July 29, 2024.

globenewswire.com

T2 Biosystems Regains Compliance with Nasdaq Continued Listing Requirements

LEXINGTON, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it received written notice from the Nasdaq Stock Market LLC (“Nasdaq”) on May 21, 2024 informing the Company that it has regained compliance with the market value of listed securities (“MVLS”) requirement, as set forth in Nasdaq Listing Rule 5550(b)(2) (the “Rule”) for continued listing on the Nasdaq Capital Market.

globenewswire.com

T2 Biosystems Announces Closing of $8 Million Private Placement Priced At-The-Market Under Nasdaq Rules

LEXINGTON, Mass., May 17, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has closed its previously announced private placement for the purchase and sale of an aggregate of 2,025,317 shares of common stock (or pre-funded warrant in lieu thereof), series A warrants to purchase up to 2,025,317 shares of common stock and short-term series B warrants to purchase up to 2,025,317 shares of common stock at a purchase price of $3.95 per share of common stock (or per pre-funded warrant in lieu thereof) and accompanying warrants priced at-the-market under Nasdaq rules. The series A warrants and short-term series B warrants have an exercise price of $3.70 per share and are exercisable immediately upon issuance. The series A warrants will expire five and one-half years from the date of issuance and the short-term series B warrants will expire eighteen months from the date of issuance.

globenewswire.com

T2 Biosystems Announces $8 Million Private Placement Priced At-The-Market Under Nasdaq Rules

LEXINGTON, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 2,025,317 shares of common stock (or pre-funded warrant in lieu thereof), series A warrants to purchase up to 2,025,317 shares of common stock and short-term series B warrants to purchase up to 2,025,317 shares of common stock at a purchase price of $3.95 per share of common stock (or per pre-funded warrant in lieu thereof) and accompanying warrants in a private placement priced at-the-market under Nasdaq rules. The series A warrants and short-term series B warrants will have an exercise price of $3.70 per share and will be exercisable immediately upon issuance. The series A warrants will expire five and one-half years from the date of issuance and the short-term series B warrants will expire eighteen months from the date of issuance. The private placement is expected to close on or about May 17, 2024, subject to the satisfaction of customary closing conditions.

globenewswire.com

T2 Biosystems Announces CRG's Conversion from Preferred Stock to Common Stock

LEXINGTON, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that entities affiliated with CRG Servicing LLC (“CRG”) have converted Series A and Series B Convertible Preferred Stock to Common Stock.

globenewswire.com

T2 Biosystems Announces Letter of Intent to Enter Strategic Partnership for Lyme Disease

Advances plan to launch T2Lyme Panel for detection of early Lyme disease Advances plan to launch T2Lyme Panel for detection of early Lyme disease

globenewswire.com

T2 Biosystems, Inc. (TTOO) Q1 2024 Earnings Call Transcript

T2 Biosystems, Inc. (NASDAQ:TTOO ) Q1 2024 Earnings Conference Call May 6, 2024 4:30 PM ET Company Participants Philip Taylor - IR, Gilmartin Group John Sperzel - Chairman & CEO John Sprague - CFO Conference Call Participants Kyle Mikson - Canaccord Operator Greetings. Welcome to the T2 Biosystems, Inc. First Quarter 2024 Earnings Conference Call.

seekingalpha.com

T2 Biosystems Announces First Quarter 2024 Financial Results

Achieved double-digit growth in sepsis product revenue and reduced debt by approximately 80% compared to the prior year period Achieved double-digit growth in sepsis product revenue and reduced debt by approximately 80% compared to the prior year period

globenewswire.com

T2 Biosystems Announces Commercial Expansion Through Middle East Distributor

Filed Pursuant to Rule 433 Issuer Free Writing Prospectus dated May 6, 2024 Relating to Preliminary Prospectus dated May 6, 2024 Registration No. 333-278866 LEXINGTON, Mass.

globenewswire.com

T2 Biosystems Announces the Conversion of an Additional $15 Million of CRG Term Loan into Equity

Strengthens balance sheet by reducing total debt by approximately 80% over the past year Strengthens balance sheet by reducing total debt by approximately 80% over the past year

globenewswire.com

T2 Biosystems to Report First Quarter 2024 Financial Results and Business Updates on May 6, 2024

LEXINGTON, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report financial results for the first quarter 2024 and business updates after market close on Monday, May 6, 2024. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.

globenewswire.com

T2 Biosystems Shareholders Vote for CRG Debt Conversion into Equity

LEXINGTON, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced results from the special meeting of stockholders on April 11, 2024. T2 Biosystems Stockholders voted for the approval of conversion of $15 million of its term loan with entities affiliated with CRG Servicing LLC (“CRG”) into T2 Biosystems equity.

globenewswire.com

T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc.

LEXINGTON, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that its multi-year capital equipment supplier agreement with Vizient, Inc., the largest member-driven health care performance improvement company in the United States, has been extended through March 31, 2025. The products covered under the contract with Vizient include the T2Dx® Instrument, the T2Bacteria® Panel and the T2Candida® Panel, which detect sepsis-causing bacterial and fungal pathogens directly from whole blood.

globenewswire.com

T2 Biosystems Unveils T2Lyme Launch Plans and Provides Additional Business Updates

Anticipates commercial launch of the T2Lyme Panel in the third quarter of 2024 Anticipates commercial launch of the T2Lyme Panel in the third quarter of 2024

globenewswire.com

T2 Biosystems to Host Investor Call on March 20, 2024 to Unveil its T2Lyme Launch Plans and Provide Additional Business Updates

LEXINGTON, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that Company management will host a conference call to discuss the T2Lyme Panel launch plans and provide additional business updates before market open on Wednesday, March 20, 2024 beginning at 8:30 a.m. Eastern Time.

globenewswire.com

T2 Biosystems Announces New Publication Highlighting the Clinical Benefits and Performance of the T2Resistance Panel

Study demonstrates T2Resistance Panel utilization enables faster targeted therapy based on direct-from-blood detection of resistance genes Study demonstrates T2Resistance Panel utilization enables faster targeted therapy based on direct-from-blood detection of resistance genes

globenewswire.com

TTOO Stock: T2 Biosystems Has Until May 20 to Regain Nasdaq Compliance

Shares of T2 Biosystems (NASDAQ: TTOO ) stock are rising higher after the medical diagnostics company disclosed that the Nasdaq Hearings Panel had provided it with an extension to regain compliance. T2 will have until May 20 to maintain a closing market capitalization of at least $35 million for at least 10 consecutive trading days.

investorplace.com

T2 Biosystems Receives Extension to Comply with Nasdaq Listing Requirement

LEXINGTON, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that the Nasdaq Hearings Panel has granted the Company's request for continued listing on the Nasdaq Stock Market, subject to the Company demonstrating compliance with Nasdaq's market value of listed securities (“Market Value”) requirement, as set forth in Nasdaq Listing Rule 5550(b)(2) (the “Rule”) on or before May 20, 2024.

globenewswire.com

T2 Biosystems (TTOO) share price stays stable post Q4 earnings

T2 Biosystems Inc. (TTOO), a prominent player in the field of medical diagnostics, recently announced its financial results for the fourth quarter of 2023, signaling a pivotal moment for the company.

invezz.com

T2 Biosystems, Inc. (TTOO) Q4 2023 Earnings Call Transcript

seekingalpha.com

T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2023 Financial Results

Advanced multiple new products and achieved record fourth quarter U.S. T2Bacteria Panel sales Advanced multiple new products and achieved record fourth quarter U.S. T2Bacteria Panel sales

globenewswire.com

T2 Biosystems Announces Agreement with CRG for the Conversion of $15 Million of CRG Term Loan into Equity

LEXINGTON, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced the entrance into a definitive agreement to convert $15 million of its term loan with entities affiliated with CRG Servicing LLC (“CRG”) into T2 Biosystems equity upon stockholder approval.

globenewswire.com

T2 Biosystems Announces Commercial Expansion Through Distributors in Europe and Asia

LEXINGTON, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistant genes, today announced the execution of territory exclusive distribution agreements for new geographies in the Netherlands, Belgium, and Vietnam, as well as the re-entry into Switzerland. Under the terms of the agreements, T2 Biosystems will sell the T2Dx® Instrument, the T2Bacteria® Panel, the T2Candida® Panel, and the T2Resistance® Panel into these countries through our distribution partners.

globenewswire.com

T2 Biosystems Receives 510(K) Clearance for Its Bacteria Panel

Shares of T2 Biosystems (NASDAQ: TTOO ) are jumping higher by more than 30%. This comes as the diagnostics company announced that it had received U.S. Food and Drug Administration (FDA) 510(k) clearance for Acinetobacter baumannii (A.

investorplace.com

T2 Biosystems Receives FDA 510(k) Clearance for the Expanded T2Bacteria Panel

Increases number of bacteria species detected with addition of Acinetobacter baumannii Increases number of bacteria species detected with addition of Acinetobacter baumannii

globenewswire.com

T2 BioSystems stock: brace for TTOO volatility this week

T2 BioSystems (NASDAQ: TTOO) stock price has moved from one of the most popular names in Wall Street into a forgotten one. The shares have gone nowhere since October and are now sitting near their lowest level on record.

invezz.com

T2 Biosystems to Report Fourth Quarter and Full Year 2023 Financial Results and Business Updates on February 15, 2024

LEXINGTON, Mass., Feb. 07, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report financial results for the fourth quarter and full year 2023 and business updates after market close on Thursday, February 15, 2024. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.

globenewswire.com

U.S. Department of Health and Human Services and Steven and Alexandra Cohen Foundation Name T2 Biosystems a Phase 2 Winner in the LymeX Diagnostics Prize

LEXINGTON, Mass., Feb. 07, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that the U.S. Department of Health and Human Services (“HHS”) and the Steven & Alexandra Cohen Foundation (“Cohen Foundation”) have selected T2 Biosystems as a Phase 2 winner in the LymeX Diagnostics Prize, a prize competition to accelerate the development of Lyme disease diagnostics. As a Phase 2 winner, T2 Biosystems will receive $265,000.

globenewswire.com

T2 Biosystems Announces Participation in NIH-funded Antibacterial Resistance Leadership Group (ARLG) Pilot Study for Pneumonia Patients

LEXINGTON, Mass., Jan. 18, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced participation in the NIH-funded Antibacterial Resistance Leadership Group (ARLG) pilot study for pneumonia patients. The Pneumonia Direct Pilot study is a prospective, observational, diagnostic, feasibility study to determine the accuracy of multiple pathogen- and host-directed tests for the diagnosis of ventilator-associated pneumonia (VAP). Under the direction of Kimberly Hanson, M.D., University of Utah, the study seeks to explore new approaches for diagnosing VAP along with more comprehensive detection of antibiotic-resistant infections. The feasibility design is intended to inform future interventional studies that will investigate the clinical impact of combined pathogen and host-directed testing approaches.

globenewswire.com

T2 Biosystems Announces FDA 510(k) Submission to Expand Use of the FDA-Cleared T2Candida Panel to Include Pediatric Testing

LEXINGTON, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) to expand the use of its FDA-cleared T2Candida® Panel to include pediatric testing.

globenewswire.com

What's going on with T2 Biosystems (TTOO) stock?

T2 BioSystems (NASDAQ: TTOO) stock price rose by more than 23% on Tuesday amid a short-squeeze and as some investors bought the dip. The shares jumped to a high of $4.81, its highest point sice mid-November.

invezz.com

T2 Biosystems (TTOO) stock price volatility has died: buy the dip?

T2 Biosystems (NASDAQ: TTOO) stock price has collapsed to a record low as concerns about the company's future continued. Shares of the popular penny stock have collapsed to a split-adjusted low of $4.72, meaning they have plunged by over 92% this year.

invezz.com

T2 Biosystems to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

LEXINGTON, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans to participate in the upcoming Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York, NY.

globenewswire.com

TTOO Stock Alert: T2 Biosystems Regains Nasdaq Compliance

T2 Biosystems (NASDAQ: TTOO ) stock is in the green after the medical diagnostics company announced that it had received written notice from the Nasdaq Listing Qualifications Staff on Oct. 31 that it had regained compliance with Nasdaq's minimum bid requirement of $1. T2 had previously enacted a 1-for-100 reverse stock split that became effective as of Oct. 12 in order to lift TTOO stock above $1.

investorplace.com

T2 Biosystems Regains Compliance with Nasdaq Listing Requirements

LEXINGTON, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that on October 31, 2023 it received written notice from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company regained compliance with the minimum bid price requirement (the “Minimum Bid Price Requirement”), as set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market.

globenewswire.com

T2 Biosystems Highlights New Clinical Data Presented at IDWeek 2023 Conference

Data demonstrates speed, accuracy, and clinical benefits of the T2Dx Instrument and T2 Biosystems' sepsis panels, including encouraging early detection data for T2Resistance Panel Data demonstrates speed, accuracy, and clinical benefits of the T2Dx Instrument and T2 Biosystems' sepsis panels, including encouraging early detection data for T2Resistance Panel

globenewswire.com

T2 Biosystems Announces Amendment and Extension of CRG Term Loan Agreement

LEXINGTON, Mass., Oct. 23, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistant genes, today announced the successful amendment and extension to its Term Loan Agreement with CRG Servicing LLC (“CRG”).

globenewswire.com

Why Is T2 Biosystems (TTOO) Stock Down 48% Today?

T2 Biosystems (NASDAQ: TTOO ) stock is plummeting lower following the company's announcement of a 1-for-100 reverse stock split and its preliminary third-quarter earnings. The reverse split was effective as of yesterday, with shares of TTOO beginning trading on a reverse split-adjusted basis as of this morning.

investorplace.com

Why Shares of T2 Biosystems Are Falling Friday

T2 Biosystems makes medical diagnostic testing equipment. The company reported a likely 60% in revenue in a preliminary third-quarter earnings report.

fool.com

T2 Biosystems, Inc. (TTOO) Preliminary Q3 2023 Earnings Call Transcript

T2 Biosystems, Inc. (NASDAQ:TTOO ) Preliminary Q3 2023 Earnings Call Transcript October 12, 2023 4:30 PM ET Company Participants Trip Taylor - IR John Sperzel - Chairman & CEO Conference Call Participants Kyle Mikson - Canaccord Ben Haynor - Alliance Global Partners Operator Greetings. Welcome to T2 Biosystems Preliminary Third Quarter 2023 Financial Results and Business Update Call.

seekingalpha.com

T2 Biosystems Announces Preliminary Third Quarter 2023 Financial Results and Business Updates

Received FDA 510(k) clearance for the T2Biothreat Panel and significantly strengthened balance sheet Received FDA 510(k) clearance for the T2Biothreat Panel and significantly strengthened balance sheet

globenewswire.com

T2 Biosystems Announces FDA 510(k) Submission to Expand the Pathogen Detection on its FDA-Cleared T2Bacteria Panel to Include Detection of Acinetobacter baumannii

LEXINGTON, Mass., Oct. 12, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) to expand the number of pathogens detected on the FDA-cleared T2Bacteria® Panel to include the detection of Acinetobacter baumannii (A. baumannii).

globenewswire.com

TTOO Stock Alert: T2 Biosystems Announces Reverse Stock Split

Shares of T2 Biosystems (NASDAQ: TTOO ) are cratering lower today. This comes after the in vitro diagnostics company announced that its board of directors approved a 1-for-100 reverse stock split.

investorplace.com

T2 Biosystems Announces Reverse Stock Split Effective Today

TTOO common stock expected to begin trading on a split-adjusted basis on October 13, 2023 TTOO common stock expected to begin trading on a split-adjusted basis on October 13, 2023

globenewswire.com

TTOO stock price: brace for T2 Biosystems volatility after earnings

T2 Biosystems (NASDAQ: TTOO) stock price will be in the spotlight on Thursday as the company publishes its financial results. The shares jumped to a high of $0.3090, a few points above this month's low of $0.1500.

invezz.com

Top 3 penny stocks to day trade: HUBC, TTOO, NVOS

Penny stocks are highly popular among day and swing traders because of their low prices and volatility. Most of these stocks are usually bad long-term investments because of their unprofitability, especially in a high-interest rates environment.

invezz.com

Penny Stocks To Buy Now? 3 To Watch In The Stock Market Today

If you're wondering what's going on in the stock market today, or trying to find the best penny stocks to buy now, understand that global tensions have heated up over the weekend in the Middle East. This followed an incursion by armed militants into Israeli territory.

pennystocks.com

T2 Biosystems Reports Granting of Inducement Award

LEXINGTON, Mass., Oct. 06, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens, announced today that it issued inducement awards to nine new employees.

globenewswire.com

Why Are Stocks Down Today?

Stocks are down on Friday as investors react to the latest data from the September job report! The reason that stocks are down today is the economy added 336,000 jobs in September.

investorplace.com

Dear TTOO Stock Fans, Mark Your Calendars for Oct. 12

T2 Biosystems (NASDAQ: TTOO ) announced today that it would report its preliminary quarterly earnings and provide business updates after the market closes on Oct. 12. In early trading, TTOO stock is jumping 20%.

investorplace.com

Spiking long yields are a danger for markets: here's what may happen next and 5 things investors should do

There's been a lot of angst about 1987 of late. In October that year, the market suffered a sharp decline that climaxed with ‘Black Monday' on the 19th, when the Dow Jones Industrial Average plunged 22.6%.

marketwatch.com

T2 Biosystems to Report Preliminary Third Quarter 2023 Financial Results and Business Updates on October 12, 2023

LEXINGTON, Mass., Oct. 05, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report preliminary financial results for the third quarter 2023 and business updates after market close on Thursday, October 12, 2023. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.

globenewswire.com

‘One percenter depression' and giant sector rotation: How a hedge fund manager sees bond crisis playing out.

“There is no magic level of yields that, when reached, will automatically draw in enough buyers to spark a sustained bond rally.”

marketwatch.com

The ‘wild bunch' have taken control of the bond market. Here's where they could wreak havoc next.

The bond market is front and center for investors these days, with JPMorgan warning of a “financial accident” if yields keep going up, driving prices lower.

marketwatch.com

TTOO Stock Alert: A Key Investor Just Dumped Another 13 Million Shares

Another day, another sale of T2 Biosystems (NASDAQ: TTOO ) for 10% owner CR Group (CRG). Since Sept.

investorplace.com

The Cost to Borrow T2 (TTOO) Stock Is Up 130% in Just 10 Days

Shares of T2 Biosystems (NASDAQ: TTOO ) are up by over 20% today on the heels of receiving U.S. Food and Drug Administration (FDA) 510(k) clearance for its T2Biothreat Panel. The panel is a direct-from-blood molecular diagnostic test that has the ability to simultaneously detect six biothreat pathogens.

investorplace.com

CR Group Just Sold More Shares of T2 Biosystems (TTOO) Stock

Shares of beleaguered biotechnology specialist T2 Biosystems (NASDAQ: TTOO ) continue their worrying descent despite the announcement of positive news. Most alarmingly, a major investor has been exiting out of TTTO stock in recent days.

investorplace.com

TTOO stock price outlook as big shareholder dumps shares

T2 Biosystems (NASDAQ: TTOO) stock price sell-off continued as the company continued facing numerous headwinds. The shares dropped to a low of $0.1884 on Tuesday, the lowest level since August 2nd.

invezz.com

CR Group Just Sold 10 Million Shares of T2 (TTOO) Stock

Among the small-cap stocks garnering attention today is T2 Biosystems (NASDAQ: TTOO ). Shares of TTOO stock are down more than 14% in afternoon trading on an announcement that a key investor is in selling mode.

investorplace.com

Bill Ackman says go short the long bond. Here's why.

Early futures action indicates Friday may see the S&P 500 SPX recover a small portion of the 2.8% lost over just the last three sessions.

marketwatch.com

T2 Biosystems' stock extends losing streak despite FDA approval for anthrax and plague diagnostic test

Shares of T2 Biosystems Inc. extended their losing streak to two days Wednesday despite the biotech clinching regulatory approval for a key diagnostic test.

marketwatch.com

T2 Biosystems reaches regulatory milestone that could be a game changer, analyst says

T2 Biosystems Inc., a Lexington, Mass.-based developer of diagnostics for rapid identification of dangerous pathogens, has reached a key regulatory milestone that could alter its near-term future, according to one analyst.

marketwatch.com

TTOO Stock Alert: T2 Confirms FDA Clearance for Biothreat Panel

T2 Biosystems (NASDAQ: TTOO ) stock can officially be added to an unfortunate list that includes fellow meme stocks Mullen Automotive (NASDAQ: MULN ) and Meta Materials (NASDAQ: MMAT ). What's the list?

investorplace.com

T2 Biosystems Receives FDA 510(k) Clearance for the T2Biothreat Panel

The only FDA-cleared multi-target biothreat product developed and manufactured by a U.S. owned company The only FDA-cleared multi-target biothreat product developed and manufactured by a U.S. owned company

globenewswire.com

Why Is T2 Biosystems (TTOO) Stock Up 30% Today?

T2 Biosystems (NASDAQ: TTOO ) stock is the top-trending ticker on social media, and its shares are up over 30% today after the Food and Drug Administration (FDA) allowed the company to start marketing its biothreat panel in America. More About the FDA's Decision and T2's Biothreat Panel Over the weekend, the FDA disclosed that it had determined that T2's Biothreat Panel was “Substantially Equivalent” to an existing product that the agency has already approved.

investorplace.com

TTOO stock price is flying: How high can T2 Biosystems go?

T2 Biosystems (NASDAQ: TTOO) stock price made a strong comeback during the pre-market session as investors bought the dip. The shares surged by more than 40%, its best daily performance since August.

invezz.com

Best Penny Stocks To Watch? 3 For Your List In September

Today we look at some of the most active penny stocks to watch. If you're new to trading, in general, we'll first go into some of the ins and outs of trading, including a background on low-priced stocks.

pennystocks.com

‘Emerging markets have a China problem.' This strategist favors India, which just hit a record.

Bank of America's global fund manager survey this week reported the biggest ever push into the U.S., and exit from emerging markets, on record. That result didn't come as a big surprise to Matt Orton, chief market strategist at Raymond James Investment Management.

marketwatch.com

Why Are Airline Stocks Down Today?

Airline stocks are down on Wednesday as a variety of factors are weighing on the sector and dashing investors' hopes. Starting off the bad news for airline stocks today are expectations for fuel prices to remain high.

investorplace.com

TTOO Stock Alert: T2 Reschedules Annual Meeting to Sept. 15

Shareholders of T2 Biosystems (NASDAQ: TTOO ) stock will have to wait a bit longer for the company to hold its 2023 annual meeting of stockholders. Yesterday, the diagnostics company announced that it would reschedule the meeting to Sept.

investorplace.com

The Fun Is Over for TTOO Stock

In early August, I wrote about how shares of T2 Biosciences (NASDAQ: TTOO ) could rise to $1 or more in a short-term frenzy. Meme investors had singled out the stock, and heavy options trading meant shares were at risk of getting squeezed.

investorplace.com

Morgan Stanley says it's a lonely bull, recommending government bonds

Morgan Stanley strategists have been almost apologetic about their view that the stock market would struggle, in a year in which the S&P 500 SPX has gained 16%. But less remarked upon is that the investment bank's team made another wrong call, in being bullish government bonds.

marketwatch.com

T2 Biosystems to Participate in the Gilmartin Group Emerging Growth Company Showcase

LEXINGTON, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans to participate in the upcoming Gilmartin Group Emerging Growth Company Showcase, taking place virtually. Members of management are scheduled to host a fireside chat on Thursday, September 21, 2023, at 10:30am ET.

globenewswire.com

Dear TTOO Stock Fans, Mark Your Calendars for Sept. 12

Shares of T2 Biosystems (NASDAQ: TTOO ) stock are currently trading below $1. However, the company's upcoming annual meeting of stockholders seeks to resolve this.

investorplace.com

Best Penny Stocks To Buy Now? 4 To Watch Before Labor Day

When it comes to stock trading, penny stocks stand out, captivating many with the promise of substantial returns. These stocks, often priced under $5 per share, belong to smaller companies and typically don't trade on the major stock exchanges.

pennystocks.com

Hedge funds have made a huge push into risky assets. Here's what that means.

Tuesday's pop for stocks after some grim job opening data helped the S&P 500 and other indexes trim August losses, though landing in the green for the month still looks like a long shot. Futures suggest a struggle for Wednesday.

marketwatch.com

Best Penny Stocks To Buy Now? 10 Under $1 To Watch

The traditional approach to investing is finding well-established companies, investing in them and waiting years for a return of 50%. But in today's fast-paced stock market, retail traders are finding better ways to use the stock market to capture gains.

pennystocks.com

T2 Biosystems Praises CDC's Actions Aimed at Optimizing U.S. Hospital Sepsis Programs

The U.S. Centers for Disease Control and Prevention Releases 2023 Hospital Sepsis Program Core Elements The U.S. Centers for Disease Control and Prevention Releases 2023 Hospital Sepsis Program Core Elements

globenewswire.com

TTOO stock price has recoiled: Is it safe to buy T2 Biosystems?

T2 Biosystems (NASDAQ: TTOO) stock price retreated in the past few weeks as the recent rebound lost momentum. After peaking at $0.6960 this month, the shares have pulled back by ~45% to $0.40, giving it a market cap of $117 million.

invezz.com

7 Best Penny Stocks To Buy Under $1 in 2023: Big Risk, Big Return?

Penny stocks, often priced under $1, have long been the allure for many investors seeking high-risk, high-reward opportunities. These stocks, typically from smaller companies, offer the tantalizing possibility of significant returns.

pennystocks.com

T2 Biosystems Preps to Resell 141 Million Shares of TTOO Stock

T2 Biosystems (NASDAQ: TTOO ) stock is down by about 15% today after the healthcare diagnostics company filed a Form S-3. The filing documents the resale of up to 141.64 million shares from selling stockholders.

investorplace.com

TTOO Stock Alert: T2 Biosystems Seeks Approval for Reverse Stock Split

On Sept. 12, T2 Biosystems (NASDAQ: TTOO ) will hold its annual meeting of stockholders. Up for vote are a total of nine proposals, which include a reverse stock split in a range between 1-for-50 and 1-for-150.

investorplace.com

T2 Biosystems touts ‘highly differentiated' products in fight against sepsis

T2 Biosystems Inc. is offering “highly differentiated” products in the fight against sepsis, according to CEO John Sperzel.

marketwatch.com

T2 Biosystems shares retreat in extended trading after another massive session Friday

Volatility has been the name of the game for T2 Biosciences this week. Shares of the company are down more than 8% after hours Friday to $0.56 — after gaining nearly 24% during the Friday session.

proactiveinvestors.com

T2 Biosystems shares slide after snapping winning streak

T2 Biosystems (NASDAQ:TTOO) shares fell 15% at the open on Thursday after snapping its three-day winning streak the day before, down 3.8% at $0.57 at Wednesday's close. The company, which develops in vitro diagnostics tools for laboratories and hospitals, has seen its stock rally as much as more than 500% in August on meme-like buzz.

proactiveinvestors.com

T2 Biosystems stock falls 12.3% premarket after snapping 3-day winning streak

Shares of micro cap T2 Biosystems Inc. TTOO, -3.77% plunged 12.2% in premarket trades Thursday. The health diagnostics company's stock ended Wednesday's session down 3.8%, snapping a three-day winning streak.

marketwatch.com

TTOO's 375% Surge In A Month: Unveiling the Driving Forces

The small-cap penny stock market has been hot lately, with a surge in volume and activity across several names. The most in-play name, with price and volume soaring remarkably, has been T2 Biosystems NASDAQ: TTOO.

marketbeat.com

T2 Biosystems: what is it and why is it up 400% in August?

T2 Biosystems (NASDAQ:TTOO) shares have added about 400% in the last month as it became Wall Street's latest struggling stock to gain meme status. But what is it and why has it captured the attention of meme stock traders?

proactiveinvestors.com

T2 Biosystems stock climbs more than 4% premarket to continue rally

Shares of micro cap T2 Biosystems Inc. TTOO rose 4.1% in premarket trades Wednesday, continuing their rally. The health diagnostics company's stock ended Monday's session up 51.6% for their highest one-day percentage gain since Aug. 2, when the shares rose 54.3%.The stock is on a three-day winning streak.

marketwatch.com

T2 Biosystems shares fly after sparking meme-like buzz

Shares of T2 Biosystems (NASDAQ:TTOO) rose more than 35% on Tuesday, continuing the stock's two-day winning streak as the stock benefits from “meme-like” buzz. T2 Biosystems (NASDAQ:TTOO) has gained about 385% in the last month.

proactiveinvestors.com

T2 Biosystems stock surges more than 14% premarket to continue rally

Shares of micro cap T2 Biosystems Inc. TTOO rose 14.3% in premarket trades Tuesday, continuing a rally that saw the stock end Monday's session up 15.4%. The stock is on a two-day winning streak after ending Friday's session up 3.3%.

marketwatch.com

TTOO stock price is pumping: Is T2 Biosystems a good buy?

T2 Biosystems (NASDAQ: TTOO) stock has woken up recently even as concerns about the company remain. The shares soared to a high of $0.4453 last week, the highest level since April.

invezz.com

4 Meme Stocks to Sell Before They Die

This article is an excerpt from the InvestorPlace Digest newsletter. To get news like this delivered straight to your inbox, click here.

investorplace.com

T2 Biosystems shares surge on meme stock interest amid Nasdaq compliance challenges

T2 Biosystems (NASDAQ:TTOO) shares have risen almost 200% so far this month on meme stock interest, trading hands at about US$0.31 on Friday morning. Before the highly shorted healthcare stock caught the eye of meme-stock traders, it had traded at about US$0.15.

proactiveinvestors.com